Results 111 to 120 of about 2,808,349 (298)

Open-source genomic analysis of Shiga-toxin–producing E. coli O104:H4 [PDF]

open access: yes, 2011
An outbreak caused by Shiga-toxin–producing Escherichia coli O104:H4 occurred in Germany in May and June of 2011, with more than 3000 persons infected. Here, we report a cluster of cases associated with a single family and describe an open-source genomic
Antoine Danchin   +39 more
core   +1 more source

CRISPR/Cas9‐edited tumor‐associated immune cells in cancer immunotherapy

open access: yesVIEW, EarlyView.
Abstract Immuno‐oncology represents an emerging field that has significantly transformed tumor therapeutics, with immune cells serving as the cellular foundations of cancer immunotherapy. Due to its high efficiency and sensitivity, CRISPR/Cas9 genome editing is a highly promising technique for precise and rapid gene modification.
Yuhui Ma   +6 more
wiley   +1 more source

Chemistry and Structure-Activity Relationship of the Styrylquinoline-Type HIV Integrase Inhibitors

open access: yesMolecules, 2010
In spite of significant progress in anti-HIV-1 therapy, current antiviral chemo-therapy still suffers from deleterious side effects and emerging drug resistance.
Didier Desmaële   +1 more
doaj   +1 more source

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades

open access: yesJournal of Antimicrobial Chemotherapy, 2015
Objectives The aim of this study was to characterize the prevalence and patterns of genotypic integrase inhibitor (INI) resistance in relation to HIV-1 clade.
T. Doyle   +10 more
semanticscholar   +1 more source

A bidirectional fluorescent two-hybrid system for monitoring protein–protein interactions

open access: yes, 2014
Two-hybrid systems have been the cornerstone of research into protein–protein interactions, but these systems typically rely on life/death reporters that put additional selective pressure on the host organism, and potentially lead to false positives ...
Nordgren, Ida Karin, Tavassoli, Ali
core   +1 more source

Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and available of integrase inhibitors in Cape Town, South Africa [PDF]

open access: yes, 2018
HIV-Integrase (IN) has proven to be a viable target for highly specific HIV-1 therapy. We aimed to characterize the HIV-1 IN gene in a South African context and identify resistance-associated mutations (RAMs) against available first and second ...
A Hombrouck   +45 more
core   +3 more sources

Penile vascular status in young men living with HIV experiencing erectile dysfunction: A comparative cross‐sectional pilot study

open access: yesAndrology, EarlyView.
Abstract Background Erectile dysfunction in people living with HIV is a multifactorial disease, but the role of penile vascular status assessed by dynamic penile color Doppler echography is underexplored. Objectives This study assessed penile vascular status in young males living with HIV experiencing erectile dysfunction, comparing them to HIV ...
Giorgio Tiecco   +9 more
wiley   +1 more source

Potential benefit of dolutegravir once daily: efficacy and safety

open access: yesHIV/AIDS: Research and Palliative Care, 2013
Alessandra Fantauzzi,1 Ombretta Turriziani,2 Ivano Mezzaroma11Department of Clinical Medicine, 2Department of Molecular Medicine, Sapienza, University of Rome, Rome, ItalyAbstract: The viral integrase enzyme has recently emerged as a primary alternative ...
Fantauzzi A, Turriziani O, Mezzaroma I
doaj  

The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity

open access: yesRetrovirology, 2017
Background HIV-1 Integrase (IN) interacts with the cellular co-factor LEDGF/p75 and tethers the HIV preintegration complex to the host genome enabling integration.
Céline Amadori   +23 more
doaj   +1 more source

Tolerability of integrase inhibitors in a real-life setting [PDF]

open access: yesJournal of Antimicrobial Chemotherapy, 2017
Integrase inhibitors have shown better tolerability than other drugs in clinical trials, but some post-marketing data have suggested potential differences among them.We compared rates and reasons for discontinuation of raltegravir-, elvitegravir- and dolutegravir-based regimens in a large cohort of HIV-infected patients.Retrospective analysis of a ...
Judit Peñafiel   +15 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy